Compares two inhaled COPD medicines on air trapping and inflammation in the lungs
Tests triple versus dual inhaler treatment in adults with COPD, a lung disease.
Plain-language title generated from the registry record
Registry title: The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
Key facts
- Where
- Bangkoknoi, ThailandSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT06474039, who can take part
Where in Thailand
- Division of Respiratory Disease and TB, Siriraj HospitalBangkoknoi, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mahidol University
- Trial code
- NCT06474039
- Record updated
- 6 May 2025
- Original description
This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediatorsRead full original descriptionShow less
The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators
Inclusion: Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence; Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators; Patients who are able to provide informed consent.
Exclusion: - Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases; Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids; Being treated with triple therapy (ICS/LABA/LAMA); Being in terminally ill conditions.